Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | HTR5A | P47898 | 2/20 | 0.50 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28172745 | 0.77 | KDM4E (0.48) | HTR2CKDM4EMEN1KMT2AMAPT | |
| SCHEMBL31292996 | 0.77 | HTR2C (0.46) | HTR2CKDM4EMEN1KMT2AHTR2A | |
| SCHEMBL27210132 | 0.77 | HTR2C (0.46) | HTR2CHTR2AMAPK10RIPK1 | |
| SCHEMBL30477973 | 0.77 | KDM4E (0.48) | HTR2CKDM4EMEN1KMT2AMAPT | |
| SCHEMBL28357294 | 0.77 | HTR2C (0.46) | HTR2CKDM4EMEN1KMT2AHTR2A | |
| Hydrochloric Acid SCHEMBL31293257 | 0.76 | HTR2C (0.45) | HTR2CKDM4EMEN1KMT2AHTR2A | |
| SCHEMBL28357290 | 0.73 | TAAR1 (0.46) | HTR2CKDM4ETAAR1 | |
| SCHEMBL28357132 | 0.73 | HTR2C (0.63) | HTR2CHTR2A | |
| Cgs-19281A SCHEMBL2930783 | 0.73 | KDM4E (0.58) | HTR2CKDM4EMEN1KMT2AHTR2A | |
| SCHEMBL30921653 | 0.73 | KDM4E (0.58) | HTR2CKDM4EMEN1KMT2AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116332930-A | Evodiamine derivative targeting insect ryanodine receptor as well as preparation and application thereof | 天津农学院 | 2023-06-27 | — | — | CN | claimed |
| CN-112390798-A | Production process of evodiamine and method for recycling solvent used in production | 张家港威胜生物医药有限公司 | 2021-02-23 | — | — | CN | claimed |
| CN-108969770-A | 1- methyl -3- methylol-tetrahydro-beta-carboline of dipeptides modification, synthesis and application | 首都医科大学 | 2018-12-11 | — | — | CN | claimed |
| CN-107686482-A | New heptacyclic compound, it is synthesized, activity rating and application | 首都医科大学 | 2018-02-13 | — | — | CN | claimed |
| CN-103159827-B | (1R, 3S)-1-p-nitrophenyl-tetrahydro-beta-carboline amic acid, its synthesis, anti-thrombus activity and application | Capital Medical University (CN) | 2016-03-30 | — | — | CN | claimed |
| CN-103159758-B | (1S, 3S)-1-p-nitrophenyl-1,2,3,4-tetrahydro-beta-carboline amic acid, its synthesis, anti-thrombus activity and the application as antithrombotic agent | Capital Medical University (CN) | 2015-08-05 | — | — | CN | claimed |
| CN-103159758-A | (1S,3S)-1-p-nitrophenyl-1,2,3,4-tetrahydro-beta-carboline acyl amino acid, and synthesis, antithrombotic activity and application as antithrombotic agent thereof | UNIV CAPITAL MEDICAL | 2013-06-19 | — | — | CN | claimed |
| CN-103159827-A | Synthesis, anti-thrombotic activity, and application of (1R, 3S) -1-p-nitrophenyl-1,2,3,4-tetrahydro-beta-carboline acyl amino acid | UNIV CAPITAL MEDICAL | 2013-06-19 | — | — | CN | claimed |
| US-20060292202-A1 | Drug delivery device | BAUSCH & LOMB INCORPORATED | 2006-12-28 | — | — | US | claimed |
| EP-0923581-B1 | 4-SUBSTITUTED BETA-CARBOLINES AS IMMUNOMODULATORS | BOEHRINGER INGELHEIM PHARMA (US) | 2003-05-21 | — | — | EP | claimed |
| US-6093723-A | AN IMMUNOMODULATOR FOR TREATING AND PREVENTING IMMUNE DISORDERS, INCLUDING AUTOIMMUNE DISEASE, INFLAMMATORY DISEASE, ORGAN TRANSPLANT REJECTION AND OTHER DISORDERS ASSOCIATED WITH IL-2 MEDIATED IMMUNE RESPONSE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-07-25 | — | — | US | claimed |
| EP-0923581-A1 | 4-SUBSTITUTED BETA-CARBOLINES AS IMMUNOMODULATORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 1999-06-23 | — | — | EP | claimed |
| WO-1998006719-A1 | 4-SUBSTITUTED BETA-CARBOLINES AS IMMUNOMODULATORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1998-02-19 | — | — | WO | claimed |
| CN-119661519-A | Preparation method and application of novel carboline quaternary ammonium salt compound with photodynamic antibacterial effect | 常州市妇幼保健院 | 2025-03-21 | — | — | CN | disclosed |
| CN-119285651-A | Oxaevodiamine compound and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2025-01-10 | — | — | CN | disclosed |
| CN-119080622-A | (2-Nitromethyl) arylformate compound and application thereof | 中国药科大学 | 2024-12-06 | — | — | CN | disclosed |
| US-4705857-A | Indole derivatives, process for producing them and their use as intermediates | SCHERING AKTIENGESELLSCHAFT (DE) | 1987-11-10 | — | — | US | disclosed |
| US-4472399-A | Indolo[2',3';3,4]pyrido[2,1-b]quinazoline-5-ones, a process for the preparation thereof, and diuretic compositions and methods using them | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1984-09-18 | — | — | US | disclosed |
| EP-0110813-A2 | Process for producing beta-carboline derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-06-13 | — | — | EP | disclosed |
| US-4367230-A | ANTIANOXIC AGENTS | TANABE SEIYAKU CO., LTD. (JP) | 1983-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060292202-A1 | Drug delivery device | ALDH1A2, ADRB2, ADRA2B | HTR2C 449/4885KDM4E 3594/4885MEN1 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.